Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2020 - 2022)

Historic Liabilities and Shareholders Equity for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $686.6 million.

  • Atea Pharmaceuticals' Liabilities and Shareholders Equity fell 1860.43% to $686.6 million in Q3 2022 from the same period last year, while for Dec 2022 it was $2.1 billion, marking a year-over-year decrease of 3696.72%. This contributed to the annual value of $772.9 million for FY2021, which is 1050.68% down from last year.
  • As of Q3 2022, Atea Pharmaceuticals' Liabilities and Shareholders Equity stood at $686.6 million, which was down 1860.43% from $694.3 million recorded in Q2 2022.
  • Atea Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $871.5 million during Q2 2021, with a 5-year trough of $110.1 million in Q3 2020.
  • Over the past 3 years, Atea Pharmaceuticals' median Liabilities and Shareholders Equity value was $772.9 million (recorded in 2021), while the average stood at $711.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 66608.36% in 2021, then plummeted by 2033.23% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $863.6 million in 2020, then dropped by 10.51% to $772.9 million in 2021, then dropped by 11.17% to $686.6 million in 2022.
  • Its last three reported values are $686.6 million in Q3 2022, $694.3 million for Q2 2022, and $717.2 million during Q1 2022.